ACM
VRTX icon

Ashford Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Ashford Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.05M Buy
9,078
+833
+10% +$388K 0.5% 48
2025
Q4 		$3.74M Hold
8,245
– – 0.42% 55
2025
Q3 		$3.23M Buy
8,245
+538
+7% +$225K 0.36% 55
2025
Q2 		$3.43M Sell
7,707
-485
-6% -$224K 0.4% 49
2025
Q1 		$3.97M Buy
8,192
+273
+3% +$127K 0.51% 48
2024
Q4 		$3.19M Hold
7,919
– – 0.38% 51
2024
Q3 		$3.68M Sell
7,919
-481
-6% -$231K 0.46% 49
2024
Q2 		$3.94M Hold
8,400
– – 0.53% 51
2024
Q1 		$3.51M Sell
8,400
-956
-10% -$404K 0.48% 46
2023
Q4 		$3.81M Buy
9,356
+3,299
+54% +$1.22M 0.51% 46
2023
Q3 		$2.11M Sell
6,057
-420
-6% -$147K 0.31% 51
2023
Q2 		$2.28M Sell
6,477
-106
-2% -$35.7K 0.32% 46
2023
Q1 		$2.07M Buy
6,583
+7
+0.1% +$2.1K 0.31% 48
2022
Q4 		$1.9M Sell
6,576
-167
-2% -$50.9K 0.29% 49
2022
Q3 		$1.95M Sell
6,743
-2,462
-27% -$708K 0.3% 48
2022
Q2 		$2.59M Sell
9,205
-8
-0.1% -$2.14K 0.37% 49
2022
Q1 		$2.4M Sell
9,213
-544
-6% -$129K 0.26% 58
2021
Q4 		$2.14M Buy
9,757
+1,568
+19% +$305K 0.21% 62
2021
Q3 		$1.49M Buy
8,189
+1,183
+17% +$231K 0.13% 67
2021
Q2 		$1.41M Sell
7,006
-420
-6% -$87.9K 0.13% 70
2021
Q1 		$1.6M Buy
7,426
+1,717
+30% +$377K 0.15% 65
2020
Q4 		$1.35M Buy
5,709
+219
+4% +$50.2K 0.13% 67
2020
Q3 		$1.49M Sell
5,490
-361
-6% -$99.6K 0.18% 58
2020
Q2 		$1.7M Buy
5,851
+863
+17% +$234K 0.22% 55
2020
Q1 		$1.19M Buy
4,988
+228
+5% +$52.3K 0.21% 56
2019
Q4 		$1.04M Buy
4,760
+2
+0% +$405 0.14% 61
2019
Q3 		$806K Buy
4,758
+961
+25% +$170K 0.12% 69
2019
Q2 		$696K Hold
3,797
– – 0.09% 74
2019
Q1 		$698K Sell
3,797
-383
-9% -$70.7K 0.1% 75
2018
Q4 		$693K Hold
4,180
– – 0.11% 75
2018
Q3 		$806K Buy
+4,180
New +$744K 0.1% 74

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ashford Capital Management's VRTX Position: Q1 2026 in Review

Ashford Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, buying an estimated $388K and bringing the position to 9,078 shares worth $4.05M. The position accounts for 0.5% of the portfolio, ranked #48.

Ashford Capital Management first reported a position in VRTX in Q3 2018 and has held it in 31 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ashford Capital Management held 9,078 shares of Vertex Pharmaceuticals worth $4.05M as of Q1 2026.
  • Ashford Capital Management bought 833 Vertex Pharmaceuticals shares in Q1 2026, an estimated $388K.
  • Vertex Pharmaceuticals made up 0.5% of Ashford Capital Management's portfolio in Q1 2026, its #48 holding.
  • Ashford Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ashford Capital Management's 13F filing for Q1 2026, filed 15 May 2026.